AVX420 is a second-generation small molecule in the AVX family of potent and selective cPLA2α inhibitors and belongs to a chemical class of thiazolyl ketone analogues.
AVX420 inhibits cPLA2α resulting in significantly reduced levels of arachidonic acid, resulting in a pronounced effect on tumor growth inducing programmed cell death, anti-tumor inflammation, inhibition of angiogenesis, and anti-tumor proliferation.
The global therapeutics market for cancer drugs is 166 billion USD, consisting of mix of old and newer drugs. The world’s largest cancer drug is MSD’s Keytruda® (pembrolizumab) which is indicated for several cancers and has an annual turnover of 17 billion USD.
Despite available drugs like chemotherapy and immunotherapy, a large unmet need persist for new cancer treatments that are both efficacious and safe.
The global therapeutics market for cancer drugs is 166 billion USD, consisting of mix of old and newer drugs.
Series A funding and preclinical licensing deals in similar cases
Series A fundings in Europe for pre-clinical oncology companies/assets (blood and breast cancer) since 1. January 2018 has an average value of 27 mUSD. The most resent deal value of top small molecule licensing deals in breast cancer and leukemia had an average deal size of 589 mUSD.
John R. Zibert
Chief Executive Officer
Erlend P. Skagseth